Chromatin antibody selection for ChIP: what makes histone antibodies genuinely modification specific, why a histone h3 antibody against the unmodified backbone answers a different question, what a histone antibody igg preparation still owes in specificity, where a smarca4 antibody sits as a remodeller rather than a mark, and why lot variation matters more here than anywhere else

Establishing that the antibody works

1. Demand modification specificity data, not just a blot. A western blot on bulk histones shows the antibody binds something the right size. What matters is whether it discriminates between neighbouring modification states, and the evidence for that is a peptide array or a dot blot against a panel of modified peptides.
2. Run a peptide competition. Pre-incubating the antibody with the free modified peptide should abolish the signal, and the unmodified peptide should not. This is a cheap experiment in your own hands and it is the fastest way to expose a reagent that binds the backbone rather than the mark.
3. Use a genetic negative where one exists. A knockout or a point mutant of the modified residue is the strongest control available. Where the biology allows it, an enzyme inhibitor that removes the mark gives much of the same information.
4. Test the lot you will use, not the lot on the datasheet. Polyclonal chromatin antibodies vary substantially between lots, and a publication validating lot A says little about lot B. Buy enough of one lot to finish the project, and record the lot number with every experiment.
5. Include the input and a non-specific immunoglobulin. Input normalises for chromatin preparation and sonication efficiency; an isotype-matched immunoglobulin control shows the background of the procedure itself. Neither is optional and both are routinely missing from published methods.

Chromatin preparation decides half the result

Fixation time and sonication conditions change which epitopes survive and how well they are accessible. Over-fixation masks epitopes and under-fixation loses transient interactions, and both look like an antibody problem.

Check the fragment size distribution on every preparation. A ChIP that failed on chromatin fragmented to several kilobases failed at the sonicator, and no change of antibody will rescue it.

Reading a genome-wide result critically

Enrichment at known positive loci and absence at known negative ones is the minimum acceptance test before any genome-wide analysis is interpreted. Running those two quantitative measurements first costs a day and saves weeks of analysis on a failed pulldown.

Be suspicious of a profile that tracks accessibility everywhere. That pattern is what a poorly specific antibody produces, and it is easy to over-interpret because it correlates with real biology.

Buying and banking

Ask for the remaining volume of a lot before committing to it, and buy the project's supply at once. Providers will usually reserve a lot if asked, and will rarely offer.

Record the catalogue number, the lot, the dilution and the chromatin amount in the method. Published ChIP methods that omit the lot are the reason a great deal of this work does not reproduce.

Common questions

What makes a chromatin antibody suitable for ChIP?

It has to bind the epitope in fixed, fragmented chromatin rather than only on a denatured blot, and it has to discriminate the modification state. Ask for ChIP data with a genomic control region, plus peptide array specificity data.

Why does lot variation matter so much for a histone antibody?

Because most are polyclonal and the mark is a very small epitope. A new bleed is a new mixture of clones, and its discrimination between mono, di and tri methylation can differ substantially from the previous one.

Are recombinant monoclonal chromatin antibodies better?

For reproducibility, clearly yes: the sequence is fixed so the reagent is the same indefinitely. They still have to be validated for specificity, because a defined clone can be defined and wrong.

What does a peptide competition control actually prove?

That the signal depends on the epitope you think it does. It does not prove the antibody discriminates between related modifications, which is why the competition is run with both the modified and the unmodified peptide.

Browse by service class

• Compare Gene synthesis on advertised prices